In 2024, femtech companies reached a valuation of $28 billion, reflecting steady growth over the past decade, with projections to reach $60 billion by 2027. The market is expanding rapidly, fueled by growing awareness of reproductive, menopausal, and general health concerns, alongside trends in personalized healthcare, AI-powered solutions, sustainable menstrual products, and advanced menopause care. This growth is leading to the emergence and scaling of more startups in these areas.
Vestbee reached out to some of the most active investors in European femtech startups — Calm/Storm Ventures, The Case for Her, Goddess Gaia Ventures, and Joyance Partners — for their insights on the promising startups, with one condition: they could not mention any of their portfolio companies.
Philippa Allen, Junior Investment Manager at Calm/Storm Ventures
- Elsee.care is a French femtech startup founded by the fantastic duo Lara Royers, a serial entrepreneur, and Eugenie Beauchesne, who was formerly with France’s healthtech unicorn, Alan. Their mission is to provide women’s well-being services that are often overlooked or inadequately covered by traditional private health insurance.
- Ovom is a digital-first reproductive care clinic. By using AI, they are able to personalize and optimize the ideal healthcare path for each user to reduce the number of treatment cycles needed for successful outcomes.
Gerda Mazi Larsson, co-founder of The Case for Her
- Hey Jane is a telehealth company that provides access to medication abortion in the US, offering support to patients from the start to the end of their needs.
- Tia is a women's health one-stop shop that delivers both physical and digital care across the women's health spectrum and is designed by and for women.
- Aoa Dx was created to ensure that women have access to the most innovative early detection platform in their fight against cancer.
- Flex provides a variety of sustainably and ethically sourced menstrual products.
Chloe Roesler, VC Fellow at Goddess Gaia Ventures
- Hertility is revolutionizing female reproductive healthcare through accessible at-home hormone and fertility tests and clinical trial research. With a high impact, 44% of women who take Hertility's test receive diagnoses indicative of a reproductive condition, highlighting the importance of their service.
- Jack Fertility offers at-home fertility testing kits for male sperm quality, addressing an often-overlooked aspect of reproductive health. Most of the time, fertility issues and reproductive obstacles tend to fall on women, but Jack Fertility is tackling this disparity and changing the narrative.
- Panakeia leverages AI technology to provide rapid molecular analyses of patient tissues. Their innovative approach to multi-omics will make clinical diagnostics and drug development significantly more efficient.
- Nostos Genomics has developed AI-powered software to interpret genetic data in less than 2 minutes. Their automated technology is fascinating, improving the speed and accuracy of rare diseases diagnoses.
- Nima Life is the first reproductive health platform that provides pregnancy loss test kits to diagnose and explain female fertility issues. They are at a very early stage, having developed through the BioInnovation Institute, providing personalized, evidence-based insights to help women increase chances of successful pregnancy.
Jun Deng, Investment Partner at Joyance Partners
- Mae is a culturally competent maternal health platform, connecting expectant mothers with critical resources to drive positive pregnancy outcomes.
- Attn:Grace is the first sustainable wellness brand for women, by women, with products thoughtfully tailored to women's changing needs.
- Madorra provides a nonhormonal and noninvasive solution to vaginal dryness with a focus on post-menopausal people and breast cancer survivors.
